

COMMUNICATIONS ORALES

Presentation ID 881

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Christian Recher

Presentation ID 43

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Christian Recher

Presentation ID 450

Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a datam registry study.

Christian Recher

Presentation ID 497

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

Anais Schavgoulidze

Presentation ID 991

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli

Presentation ID 918

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

Auteur Oncopole : Liliana Lucca, Ossama Kohil, Marine Cuisinier, Marie-véronique Joubert, Nadège Carrié , Anaïs Schavgoulidze, Benjamin Hebraud,,Jill Corre, Aurore Perrot , Herve Avet-Loiseau

Ludovic Martinet

TOUS LES ABSTRACTS

ABSTRACT ID abs25-11651

ABSTRACT ID 26

Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial

Auteur Oncopole = Christian RECHER

ABSTRACT ID abs25-11922

ABSTRACT ID 37

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Auteur Oncopole : Christian RECHER

ABSTRACT ID abs25-1871

ABSTRACT ID 43

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

1^{er} auteur : Christian RECHER

ABSTRACT ID abs25-1993

ABSTRACT ID 58

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)

Auteur Oncopole : Lucie OBERIC

ABSTRACT ID abs25-1663

ABSTRACT ID 77

Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC

Auteur Oncopole : Lucie Rigolot, Françoise Huguet

ABSTRACT ID abs25-4452

ABSTRACT ID 101

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

Auteur Oncopole : Aurore Perrot

ABSTRACT ID abs25-12398

ABSTRACT ID 127

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lisa study from the descar-T registry

Auteur Oncopole : Pierre Bories

ABSTRACT ID abs25-2077

ABSTRACT ID 250

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

2^{ème} Auteur : Pierre Bories

ABSTRACT ID abs25-11921

ABSTRACT ID 347

Relationship between salvage strategy and outcomes in patients with CBF or NPM1-mutated AML and first molecular relapse

2^{ème} Auteur : Jules Higue

ABSTRACT ID abs25-12860

ABSTRACT ID 364

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Auteur Oncopole : Jill Corre

ABSTRACT ID abs25-4552

ABSTRACT ID 366

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Auteur Oncopole : Jill Corre

ABSTRACT ID abs25-10098

ABSTRACT ID 367

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Auteur Oncopole : Aurore Perrot, Jill Corre, Hervé Avet-Loiseau

ABSTRACT ID abs25-9861

ABSTRACT ID 368

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Auteur Oncopole : Jill Corre

ABSTRACT ID abs25-8107

ABSTRACT ID 450

Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study.

1^{er} auteur : Christian Recher // Auteur Oncopole : Suzanne Tavitian , Anne Huynh, Alban Canali , , Eric Delabesse , Véronique De Mas, Audrey Sarry, Madeline Mougenot , Sarah Bertoli

ABSTRACT ID abs25-9917

ABSTRACT ID 456

Frequency and impact of FLT3-ITD microclones in younger AML patients

Auteur Oncopole : Sarah Bertoli , Suzanne Tavitian

ABSTRACT ID abs25-11339

ABSTRACT ID 480

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Auteur Oncopole : Loic Ysebaert

ABSTRACT ID abs25-8689

ABSTRACT ID 493

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Auteur Oncopole : François Vergez, Hervé Avet-Loiseau

ABSTRACT ID abs25-8970

ABSTRACT ID 497

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

1^{er} auteur : Anaïs Schavgoulidze

ABSTRACT ID abs25-10234

ABSTRACT ID 498

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Auteur Oncopole : Aurore Perrot, Jill Corre, Hervé Ave-Loiseau

ABSTRACT ID abs25-2143

ABSTRACT ID 506

Haplo-identical transplantation in patients with myelofibrosis, a phase 2 prospective multicentric study

Auteur Oncopole : Anne Huynh

ABSTRACT ID abs25-4424

ABSTRACT ID 553

Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma

Auteur Oncopole : Camille Laurent

ABSTRACT ID abs25-2841

ABSTRACT ID 569

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

Auteur Oncopole : Loic Ysebaert

ABSTRACT ID abs25-2780

ABSTRACT ID 643

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Auteur Oncopole : 2^{ème} auteur Françoise Huguet / Eric Delabesse

ABSTRACT ID abs25-738

ABSTRACT ID 669

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Auteur Oncopole : Pierre Bories

ABSTRACT ID abs25-4430

ABSTRACT ID 684

Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.

Dernier Auteur Oncopole : Loic Ysebaert

ABSTRACT ID abs25-5814

ABSTRACT ID 744

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Auteur Oncopole : Aurore Perrot

ABSTRACT ID abs25-1873

ABSTRACT ID 881

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Auteur Oncopole : 1^{er} Auteur Christien Recher / Caroline Bonmati, Sarah Bertoli, Isabelle Luquet, Eric Delabesse

ABSTRACT ID abs25-4632

ABSTRACT ID 894

Prognostic value of baseline metabolic tumor volume from lisa ro-CHOP trial inpatients with previously untreated peripheral T-cell lymphoma

Auteur Oncopole : Loic Ysebaert

ABSTRACT ID abs25-4416

ABSTRACT ID 956

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Auteur Oncopole : Pierre Bories

ABSTRACT ID abs25-2136

ABSTRACT ID 991

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Auteur Oncopole : 1^{er} auteur Sarah Bertoli / Camille Gondran, Laetitia Largeaud, Véronique De Mas / Dernier auteur Christian Recher

ABSTRACT ID abs25-4275

ABSTRACT ID 994

Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.

Auteur Oncopole : Sarah Bertoli

ABSTRACT ID abs25-4623

ABSTRACT ID 1014

Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)

Auteur Oncopole : Pierre Bories

ABSTRACT ID abs25-14383

ABSTRACT ID 1030

Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers

Auteur Oncopole :Jill Corre, Hervé Avet-Loiseau

ABSTRACT ID abs25-1453

ABSTRACT ID 1251

Comparative risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag versus romiplostim: A target trial emulation in the french adult immune thrombocytopenia (FAITH) cohort

Auteur Oncopole : 1^{er} auteur Jérémy Zordan, Yoann Zadro

ABSTRACT ID abs25-13029

ABSTRACT ID 1507

PPM1D mutations confer resistance to venetoclax in pre-leukemic and AML populations

Auteur Oncopole : 1^{er} auteur Jules Higue, Lucie Rigolot, Véronique De Mas, Eric Delabesse, Christian Recher

ABSTRACT ID abs25-1523

ABSTRACT ID 1658

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

Auteur Oncopole : Sarah Bertoli, Christian Recher

ABSTRACT ID abs25-11696

ABSTRACT ID 1682

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Auteur Oncopole : Suzanne Tavitian

ABSTRACT ID abs25-14246

ABSTRACT ID 1744

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

Auteur Oncopole : Inès Vergnolle 2 , Laetitia Largeaud 2 , Lucie Donaty 2, Leopoldine Lapierre 3 , Lucie Rigolot2 , Véronique De Mas 2 , Suzanne Tavitian 3 , Alban Canali2 , Isabelle Luquet2 , Audrey Sarry 3 , Madeline Mougenot3 , Eric Delabesse 2 , Sarah Bertoli3 , Christian Recher3 , **Dernier auteur** Francois Vergez 2

ABSTRACT ID abs25-7512

ABSTRACT ID 1842

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Auteur Oncopole : Anne Huynh

ABSTRACT ID abs25-13340

ABSTRACT ID 1853

Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort

Auteur Oncopole : Cécile Borel

ABSTRACT ID abs25-4432

ABSTRACT ID 1958

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Auteur Oncopole : Loic Ysebaert

ABSTRACT ID abs25-7637

ABSTRACT ID 2025

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Auteur Oncopole : Christian Recher

ABSTRACT ID abs25-8391

ABSTRACT ID 2147

Downregulation of midnolin mediating non-ubiquitin protein degradation and its role in myelomagenesis.

Auteur Oncopole : Anais Schavgoulidze

ABSTRACT ID abs25-12122

ABSTRACT ID 2163

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Auteur Oncopole : Hervé Avet-Loiseau

ABSTRACT ID abs25-7770

ABSTRACT ID 2267

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Auteur Oncopole : Aurore Perrot

ABSTRACT ID abs25-9923

ABSTRACT ID 2275

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Auteur Oncopole : Anais Schavgoulidze, Jill Corre

ABSTRACT ID abs25-11949

ABSTRACT ID 2282

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Auteur Oncopole : Aurore Perrot

ABSTRACT ID abs25-241

ABSTRACT ID 2288

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Auteur Oncopole : Jill Corre

ABSTRACT ID abs25-2526

ABSTRACT ID 2450

Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry

Auteur Oncopole : Anne Huynh

ABSTRACT ID abs25-14156

ABSTRACT ID 2476

Hallmarks of allogeneic hematopoietic cell transplant success: A study on immune signatures and predictive features of graft versus host disease-free remission states from the SFGM-TC registry and cryostem biobank

Auteur Oncopole : Anne Huynh

ABSTRACT ID abs25-11117

ABSTRACT ID 2526

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Auteur Oncopole : Anne Huynh

ABSTRACT ID abs25-13308

ABSTRACT ID 2528

Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Auteur Oncopole : Anne Huynh

ABSTRACT ID abs25-10209

ABSTRACT ID 2744

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Auteur Oncopole : Anne Huynh

ABSTRACT ID abs25-12702

ABSTRACT ID 2764

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lisa study from descart-T and realisa registries

Auteur Oncopole : Pierre Bories

ABSTRACT ID abs25-2812

ABSTRACT ID 2944

Maternal and fetal risks in patients with sickle cell disease: Results of the retrospective drepamom study

Auteur Oncopole : Christophe FERREIRA, Thibault Comont, Jeremie Dion, Valérian RIVET, Andrea PASTISSIER, Pierre COUGOUL

ABSTRACT ID abs25-7536

ABSTRACT ID 3165

Characteristics and prognostic significance of myelodysplastic syndrome (MDS)-related features in vexas syndrome

Auteur Oncopole : Thibault Comont

ABSTRACT ID abs25-4535

ABSTRACT ID 3340

Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study

Auteur Oncopole : François Huguet

ABSTRACT ID abs25-11175

ABSTRACT ID 3401

Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis

Auteur Oncopole : Christian Recher

ABSTRACT ID abs25-1986

ABSTRACT ID 3419

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Auteur Oncopole : Pierre Bories

ABSTRACT ID abs25-7725

ABSTRACT ID 3429

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Auteur Oncopole : Christian Recher

ABSTRACT ID abs25-2684

ABSTRACT ID 3440

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Auteur Oncopole : Christian Recher

ABSTRACT ID abs25-2939

ABSTRACT ID 3441

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Auteur Oncopole : Sarah Bertoli

ABSTRACT ID abs25-4014

ABSTRACT ID 3443

ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (IC)

Auteur Oncopole : Christian Recher

ABSTRACT ID abs25-7256

ABSTRACT ID 3445

Impact of G-CSF in AML patients treated with venetoclax and azacitidine: A dataml registry study

Auteur Oncopole : Leopoldine Lapierre

ABSTRACT ID abs25-12002

ABSTRACT ID 3455

Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo

Auteur Oncopole : Sarah Bertoli

ABSTRACT ID abs25-15745

ABSTRACT ID 3465

Identifying patients at risk of prolonged neutropenia and enhanced risk of complications during AZA-
VEN induction for AML

Auteur Oncopole : Jules Higue

ABSTRACT ID abs25-7076

ABSTRACT ID 3620

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-
predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Auteur Oncopole : Anne Huynh

ABSTRACT ID abs25-4178

ABSTRACT ID 3773

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ)
signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the
Trial of imatinib after ponatinib induction (TIPI)

Auteur Oncopole : Françoise Huguet

ABSTRACT ID abs25-13101

ABSTRACT ID 3787

Hematopoietic architecture drives biological and metabolic heterogeneity and predicts treatment-
free remission outcomes in chronic myeloid leukemia

Auteur Oncopole : Isabelle De Araujo 1 , Mathilde Marlas 1 , Marie-Laure Nicolau 1 , Inès Vergnolle 1
, Lucie Donaty 1 , Isabelle Luquet1 , Alban Canali1 , Lucie Rigolot1 , Laetitia Largeaud 1 , Eric
Delabesse 1 , Véronique De Mas 1 , Leopoldine Lapierre 2 , Sarah Bertoli2 , Christian Recher2 , Jean-
Emmanuel Sarry 3 , Françoise Huguet2 , Suzanne Tavitian 2 , François Vergez 1

ABSTRACT ID abs25-1687

ABSTRACT ID 3875

MCL1 copy number gain is a recurrent mark of venetoclax resistance in patients with chronic
lymphocytic leukemia

Auteur Oncopole : Loïc Ysebaert

ABSTRACT ID abs25-10716

ABSTRACT ID 3932

Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma

Auteur Oncopole : Mael Penissat-mahaut, Pierre-Paul Axisa , Hélène Daunes, Marine Cuisinier, Marie-véronique Joubert, Céline Mazzotti, Anaïs Schavgoulidze, Philippe Moreau, Cyrille Touzeau, Herve Avet-Loiseau, Aurore Perrot, Jill Corre, Ludovic Martinet

ABSTRACT ID abs25-12271

ABSTRACT ID 3941

Modeling del(17p) in multiple myeloma for molecular and functional characterization

Auteur Oncopole : Anaïs Schavgoulidze

ABSTRACT ID abs25-14882

ABSTRACT ID 4026

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Auteur Oncopole : Hervé Avet-Loiseau

ABSTRACT ID abs25-7875

ABSTRACT ID 4042

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Auteur Oncopole : Aurore Perrot

ABSTRACT ID abs25-10785

ABSTRACT ID 4297

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Auteur Oncopole : Anne Huynh (1^{er} auteur)

ABSTRACT ID abs25-4174

ABSTRACT ID 4495

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

Auteur Oncopole : Loic Ysebaert

ABSTRACT ID abs25-12599

ABSTRACT ID 4541

Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descart registry by lysa

Auteur Oncopole : Pierre Bories

ABSTRACT ID abs25-7504

ABSTRACT ID 4573

Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials

Auteur Oncopole : Aurore Perrot

ABSTRACT ID abs25-7067

ABSTRACT ID 4660

Characteristics at diagnosis of autoimmune hemolytic anemias in adults: First results from a prospective, multicenter cohort of 413 patients included in the carmen-France registry

Auteur Oncopole : Yoann Zadro (1^{er} auteur), Thibault Comont

ABSTRACT ID abs25-10919

ABSTRACT ID 4818

Daratumumab can lead to long-lasting remissions in patients with refractory immune thrombocytopenia but with a high incidence of severe infections

Auteur Oncopole : Thibault Comont

ABSTRACT ID abs25-3978

ABSTRACT ID 5117

Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up

Auteur Oncopole : Françoise Huguet

ABSTRACT ID abs25-4027

ABSTRACT ID 5155

A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study

Auteur Oncopole : Odile Rauzy

ABSTRACT ID abs25-13469

ABSTRACT ID 5183

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Auteur Oncopole : François Vergez

ABSTRACT ID abs25-7546

ABSTRACT ID 5199

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Auteur Oncopole : Christian Recher

ABSTRACT ID abs25-8679

ABSTRACT ID 5200

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Auteur Oncopole : Pierre Bories

ABSTRACT ID abs25-11735

ABSTRACT ID 5203

Final results of a first-in-human Phase I study of INA03, a novel CD71/TfR1-targeted antibody-drug conjugate, in patients with relapsed or refractory acute leukemia.

Auteur Oncopole : Pierre Bories

ABSTRACT ID abs25-1542

ABSTRACT ID 5213

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

Auteur Oncopole : Christian Recher

ABSTRACT ID abs25-9469

ABSTRACT ID 5225

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Auteur Oncopole : Sarah Bertoli

ABSTRACT ID abs25-12109

ABSTRACT ID 5230

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Auteur Oncopole : Christian Recher

ABSTRACT ID abs25-1680

ABSTRACT ID 5247

Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre study.

Auteur Oncopole : Sarah Bertoli, Christian Recher

ABSTRACT ID abs25-8022

ABSTRACT ID 5295

High prognostic value of NGS-based measurable residual FLT3-ITD in AML patients positive for FLT3-ITD treated with ponatinib in combination with cytarabine in first complete remission.

Auteur Oncopole : Christian Thiede

ABSTRACT ID abs25-9630

ABSTRACT ID 5332

Circulating CD161^{high} CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)

Auteur Oncopole : Camille Laurent

ABSTRACT ID abs25-4474

ABSTRACT ID 5361

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Auteur Oncopole : Loic Ysebaert

ABSTRACT ID abs25-4201

ABSTRACT ID 5567

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies.

Auteur Oncopole : Françoise Huguet

ABSTRACT ID abs25-14128

ABSTRACT ID 5649

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Auteur Oncopole : Thibault Comont

ABSTRACT ID abs25-1900

ABSTRACT ID 5752

Adapted physical activity during first line therapy in multiple myéloma : Innovative assessment of physical status during first-line therapy in 22 multiple myeloma patients

Auteur Oncopole : Aurore Perrot

ABSTRACT ID abs25-10787

ABSTRACT ID 5836

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Auteur Oncopole : Aurore Perrot (1^{er} auteur)

ABSTRACT ID abs25-4437

ABSTRACT ID 5923

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

Auteur Oncopole : Loic Ysebaert

ABSTRACT ID abs25-14733

ABSTRACT ID 6032

Treatment of steroid-refractory acute graft-versus-host disease by mesenchymal stromal cells: The francophone society of bone marrow transplantation and cellular therapy (SFGM-TC) experience in 43 patients

Auteur Oncopole : Anne Huynh

ABSTRACT ID abs25-4621

ABSTRACT ID 6275

Progression-free survival in patients with low health-related quality of life treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial

Auteur Oncopole : Loïc Ysebaert